Johnson & Johnson

Latest Headlines

Latest Headlines

State attorneys general sue J&J over allegedly deceptive vaginal mesh marketing

Johnson & Johnson has been wading through vaginal mesh litigation, sometimes to no avail. Now the company is facing pushback from Washington and California law officials who sued J&J over its allegedly faulty implants.

Let's make a med tech deal: J&J, Medtronic, Apple, Google sit on piles of cash

Med tech is attracting a huge range of strategic investors right now. Healthcare is almost universally recognized as in need of rationalization--the application of technology in the effort to achieve better outcomes at lower costs. Medical devices and diagnostics, and the data that they generate, are expected to be central to achieving that goal in the coming decades.

J&J to enter structural heart devices, details Verb strategy in robotic surgery

Johnson & Johnson has pledged annual growth for its medical device business of about 4% to 6% through 2020. To drive that, it's looking to further enhance its fastest growing market segments while getting to market in surgical robotics and entering structural heart devices, the company told investors on May 18.

SF accelerator Highway1 debuts startups with continuous blood pressure monitor, incontinence smart patch

Hardware tech accelerator Highway1 is debuting its sixth class of startups, which includes Blumio, with its cuffless continuous blood pressure monitor, and Sensassure, with its incontinence patch that alerts caregivers when seniors need pads changed.

Hospitals to shift CMS hip, knee implant cost pressure to medical device makers: Report

Medical device makers, not hospitals, will get squeezed in the coming years as the Centers for Medicare and Medicaid (CMS) implements its value-based pricing scheme for hip and knee implant procedures. This is the first mandatory bundled payment initiative from the U.S. agency, although it previously has piloted bundled payment programs and value-based reimbursement such as penalties for hospitals with above-average patient readmissions.

Ortho after the Carlyle takeover: A Q&A with CEO Martin Madaus

Ortho Clinical Diagnostics CEO Martin Madaus told FierceMedicalDevices in an interview that Ortho has been actively investing in building out as a standalone company, which has dragged on earnings in the near term. But he added that Ortho has returned to revenue growth--and is aiming to get to about a 4% run rate.

J&J: Valuations 'still high' in med tech, as it seeks to execute on device restructure

Johnson & Johnson's medical device sales continued to slide in the first quarter, although the conglomerate, which announced a major medical device business restructuring early this year, was quick to underscore that this effort was on track and going well.

Google's Brin says med tech Verily biz is profitable--and becoming more so: Report

Google parent company Alphabet has been slow to reveal financial details on its newer businesses. But now Google co-founder and Alphabet executive Sergey Brin is starting to offer some insights. He told company employees at a recent meeting that Verily, its med tech-focused business, is already profitable on a cash basis, tech pub Re/code reported.

J&J gets FDA approval for continuous manufacturing of Prezista

It may not be anything like a meme or a juggernaut, but some definite momentum is building in pharma for continuous manufacturing. Janssen, Johnson & Johnson's generic drug unit, has won FDA approval for a continuous manufacturing line at a plant in Puerto Rico. That came just days after Eli Lilly said it would build a continuous manufacturing facility in Ireland.

Celltrion's Remicade biosim kneecapped Merck in Europe. Can it do the same to J&J in the U.S.?

The FDA has officially green-lighted the Remicade biosimilar Inflectra, a med from South Korea's Celltrion and Pfizer's Hospira. But will the knockoff be able to capture the same kind of market share from Johnson & Johnson that it's been stealing in Europe from Merck & Co.? Depends who you ask.